Next Article in Journal
Ion Channel Targeting with Antibodies and Antibody Fragments for Cancer Diagnosis
Previous Article in Journal
The Diagnostic and Clinical Utility of Autoantibodies in Systemic Vasculitis

Targeting the MHC Ligandome by Use of TCR-Like Antibodies

Department of Immunology, University of Oslo and Oslo University Hospital, N-0372 Oslo, Norway
KG Jebsen Coeliac Disease Research Centre, University of Oslo, N-0372 Oslo, Norway
Department of Biosciences, University of Oslo, N-0316 Oslo, Norway
Nextera AS, N-0349 Oslo, Norway
Author to whom correspondence should be addressed.
Antibodies 2019, 8(2), 32;
Received: 16 April 2019 / Revised: 6 May 2019 / Accepted: 7 May 2019 / Published: 9 May 2019
Monoclonal antibodies (mAbs) are valuable as research reagents, in diagnosis and in therapy. Their high specificity, the ease in production, favorable biophysical properties and the opportunity to engineer different properties make mAbs a versatile class of biologics. mAbs targeting peptide–major histocompatibility molecule (pMHC) complexes are often referred to as “TCR-like” mAbs, as pMHC complexes are generally recognized by T-cell receptors (TCRs). Presentation of self- and non-self-derived peptide fragments on MHC molecules and subsequent activation of T cells dictate immune responses in health and disease. This includes responses to infectious agents or cancer but also aberrant responses against harmless self-peptides in autoimmune diseases. The ability of TCR-like mAbs to target specific peptides presented on MHC allows for their use to study peptide presentation or for diagnosis and therapy. This extends the scope of conventional mAbs, which are generally limited to cell-surface or soluble antigens. Herein, we review the strategies used to generate TCR-like mAbs and provide a structural comparison with the analogous TCR in pMHC binding. We further discuss their applications as research tools and therapeutic reagents in preclinical models as well as challenges and limitations associated with their use. View Full-Text
Keywords: TCR-like antibodies; epitope; MHC; antigen-specific therapy TCR-like antibodies; epitope; MHC; antigen-specific therapy
Show Figures

Figure 1

MDPI and ACS Style

Høydahl, L.S.; Frick, R.; Sandlie, I.; Løset, G.Å. Targeting the MHC Ligandome by Use of TCR-Like Antibodies. Antibodies 2019, 8, 32.

AMA Style

Høydahl LS, Frick R, Sandlie I, Løset GÅ. Targeting the MHC Ligandome by Use of TCR-Like Antibodies. Antibodies. 2019; 8(2):32.

Chicago/Turabian Style

Høydahl, Lene S., Rahel Frick, Inger Sandlie, and Geir Å. Løset. 2019. "Targeting the MHC Ligandome by Use of TCR-Like Antibodies" Antibodies 8, no. 2: 32.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop